What is Apogee Therapeutics LT-Debt-to-Total-Asset?
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Apogee Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.01.
Apogee Therapeutics's long-term debt to total assets ratio
increased
from Dec. 2023 (0.00) to Dec. 2024 (0.01).
It may suggest that Apogee Therapeutics is progressively becoming more dependent on debt to grow their business.
Apogee Therapeutics LT-Debt-to-Total-Asset Historical Data
The historical data trend for Apogee Therapeutics's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Apogee Therapeutics LT-Debt-to-Total-Asset Related Terms
Thank you for viewing the detailed overview of Apogee Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APGE has been successfully added to your 